Načítá se...
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
As mesothelin is overexpressed in various types of cancer, it is an attractive target for therapeutic antibodies. T-cell bispecific antibodies bind to target cells and engage T cells via binding to CD3, resulting in target cell killing by T-cell activation. However, the affinity of the CD3-binding a...
Uloženo v:
| Vydáno v: | Biomolecules |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7175222/ https://ncbi.nlm.nih.gov/pubmed/32143496 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom10030399 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|